Alevizatos AC, McKinney RW and Feigin RD (1967). Live, attenuated Venezuelan equine encephalomyelitis virus vaccine: clinical effects in man. American Journal of Tropical Medicine and Hygiene 16: 762–768.
Altman-Hamamdzic S, Groseclose C, Ma JX, Hamamdzic D, Vrindavanam NS, Middaugh LD, Parratto NP and Sallee FR (1997). Expression of beta-galactosidase in mouse brain: utilization of a novel nonreplicative Sindbis virus vector as a neuronal gene delivery system. Gene Therapy 4: 815–822.
Balasuriya UBR, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, Hedges JF, Williams JC, Johnston RE, Wilson WD, Liu IK and Maclachlan NJ (2002). Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20: 1609–1617.
Balasuriya UBR, Heidner HW, Hedges JF, Williams JQ, Davis NL, Johnston RE and Maclachlan NJ (2000). Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. Journal of Virology 74: 10623–10630.
Berglund P, Sjoberg M, Garoff H, Atkins GJ, Sheahan BJ and Liljestrom P (1993). Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (NY) 11: 916–920.
Berglund P, Smerdou C, Flee MN, Tubulekas I and Liljestrom P (1998). Enhancing immune responses using suicidal DNA vaccines. Nature Biotechnology 16: 562–565.
Bernstein DI, Reap EI, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF and Chulay JD (2010). Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28: 484–493.
Bosworth B, Erdman MM, Stine DL, Harris I, Irwin C, Jens M, Loynachan A, Kamrud K and Harris DL (2010). Replicon particle vaccine protects swine against influenza. Comparative Immunology, Microbiology, and Infectious Diseases 33: e99–e103.
Botner A, Strandbygaard B, Sorensen KJ, Have P, Madsen KG, Madsen ES and Alexandersen S (1997). Appearance of acute PRRS-like symptoms in sow herds after vaccination with a modified live PRRS vaccine. Veterinary Record 141: 497–499.
Bredenbeek PJ, Frolov I, Rice CM and Schlesinger S (1993). Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. Journal of Virology 67: 6439–6446.
Burke DS and Ramsburg HH (1977). Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. Journal of Infectious Diseases 136: 354–359.
Carrol TD, Matzinger SR, Barro M, Fritts L, McChesney MB, Miller CJ and Johnston RE (2011). Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone in rhesus macaques. Vaccine 29: 931–940.
Ciacci-Zanella JR, Vincent AL, Prickett JR, Zimmerman SM and Zimmerman JJ (2010). Detection of anti-influenza A nucleoprotein antibodies in pigs using a commercial influenza epitope-blocking enzyme-linked immunosorbent assay developed for avian species. Journal of Veterinary Diagnostic Investigation 22: 3–9.
Dea S, Gagnon CA, Mardassi H, Pirzadeh B and Rogan D (2000). Current knowledge on the structural proteins of porcine reproductive and respiratory syndrome (PRRS) virus: comparison of the North American and European isolates. Archives of Virology 145: 659–688.
Defang GN, Khetawat D, Broder CC and Quinnan GV Jr (2011). Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29: 212–220.
Dubensky TW Jr, Driver DA, Polo JM, Belli BA, Latham EM, Ibanez CE, Chada S, Brumm D, Banks TA, Mento SJ, Jolly DJ and Chang SM (1996). Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. Journal of Virology 70: 508–519.
Erdman MM, Kamrud KI, Harris DL and Smith J (2010). Alphavirus eplicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept. Vaccine 28: 594–596.
Frolov I, Frolova E and Schlesinger S (1997). Sindbis virus replicons and Sindbis virus: assembly of chimeras and of particles deficient in virus RNA. Journal of Virology 71: 2819–2829.
Gardner JP, Frolov I, Perri S, Ji Y, MacKichan ML, Zur Megede J, Chen M, Belli BA, Driver DA, Sherrill S, Greer CD, Olten GR, Barnett SW, Liu MA, Dubensky TW and Polo JM (2000). Infection of human dendritic cells by a Sindbis viral replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. Journal of Virology 74: 11849–11857.
Geigenmuller-Gnirke U, Weiss B, Wright R and Schlesinger S (1991). Complementation between Sindbis viral RNAs produces infectious particles with a bipartite genome. Proceedings of the National Academy of Sciences of the United States of America 88: 3253–3257.
Griffin DE (2007). Alphaviruses. In: Knipe DM and Howley PM (eds) Fields Virology, 5th ednLippincott Williams & Wilkins, pp. 1023–1067.
Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, Belle BA, Catton DJ, Hsu D, Mittelstaedt D, McCormack JE, Karavodin L, Dubensky DW Jr, Chang SM and Banks TA (1998). DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. Journal of Virology 72: 950–958.
Hooper JW, Ferro AM, Golden JW, Sivera P, Dudek JM, Alterson KD, Custer M, Rivers B, Morris J, Owens G, Smith JF and Kamrud KI (2009). Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28: 494–511.
Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, Wagner J, Watson A, Negri S, Burnett BK, Graham A, Smith JF and Chulay JD (2007). Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25: 8180–8189.
Jiang W, Jiang P, Li Y, Tang J, Wang X and Ma S (2006a). Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus induce both humoral and cell-mediated responses in mice. Veterinary Immunology and Immunopathology 113: 169–180.
Jiang Y, Fang L, Xiao S, Zhang H, Pan Y, Luo R, Li B and Chen H (2006b). Immunogenicity and protective efficacy of recombinant pseudorabies virus expressing the two major membrane-associated proteins of porcine reproductive and respiratory syndrome virus. Vaccine 25: 547–560.
Jiang Y, Xiao S, Fang L, Yu X, Song Y, Niu C and Chen H (2006c). DNA vaccines co-expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus (PRRSV) display enhanced immunogenicity. Vaccine 24: 2869–2879.
Johnston LJ, Halliday GM and King NJ (2000). Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. Journal of Investigative Dermatology 114: 560–568.
Jose J, Snyder JE and Kuhn RJ (2009). A structural and functional perspective of alphavirus replication and assembly. Future Microbiology 4: 837–856.
Kamrud KI, Alterson K, Custer M, Dudek J, Goodman C, Owens G and Smith JF (2010a). Development and characterization of promotorless helper RNAs for the production of alphavirus replicon particles. Journal of General Virology 91: 1723–1727.
Kamrud KI, Alterson KD, Andrews C, Copp LO, Lewis WC, Hubby B, Patel D, Rayner JO, Talarico T and Smith JF (2008). Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. PLoS ONE 3: 1–8.
Kamrud KI, Coffield VM, Owens G, Goodman C, Alterson K, Custer M, Lewis W, Timberlake S, Wansley EK and Berglund P (2010b). In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. Journal of Virology 84: 7713–7725.
Kamrud KI, Custer M, Dudek JM, Owens G, Alterson KD, Lee JS, Groebner JL and Smith JF (2007). Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360: 376–387.
Kinney RM, Chang GJ, Tsuchiya KR, Sneider JM, Roehrig JT, Woodward TM and Trent DW (1993). Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5 ′-noncoding region and the E2 envelope glycoprotein. Journal of Virology 67: 1269–1277.
Kinney RM, Johnson BJB, Welch JB, Tsuchiya KR and Trent DW (1988). The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology 170: 19–30.
Kohno A, Emi N, Kasai M, Tanimoto M and Saito H (1998). Semliki Forest virus-based DNA expression vector: transient protein production followed by cell death. Gene Therapy 5: 415–418.
Kowalski J, Adkins K, Gangolli S, Ren J, Arendt H, DeStefano J, Obregon J, Tummolo D, Natuk R, Brown T, Parks C, Udem S and Long D (2007). Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine 25: 2296–2305.
Lee JS, Groebner JL, Hadjipanayis AG, Negley DL, Schmaljohn AL, Welkos SL, Smith LA and Smith JF (2006). Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 24: 6886–6892.
Lee JS, Hadjipanayis AG and Welkos SL (2003). Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infection and Immunity 71: 1491–1496.
Levinson R, Strauss JH and Strauss EG (1990). Determination of the complete nucleotide sequence of the genomic RNA of the O'nyong-nyong virus and its use in the construction of phylogenetic trees. Virology 175: 110–123.
Li N, Zhao JJ, Zhao HP, Sun Y, Zhu QH, Tong GZ and Qiu HJ (2007). Protection of pigs from lethal challenge by a DNA vaccine based on an alphavirus replicon expressing the E2 glycoprotein of classical swine fever virus. Journal of Virological Methods 144: 73–78.
Liljestrom P and Garoff H (1991). A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 9: 1356–1361.
Ljungberg K, Whitmore AC, Fluet ME, Moran TP, Shabman RS, Collier ML, Kraus AA, Thompson JM, Montefiori DC, Beard C and Johnston RE (2007). Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. Journal of Virology 81: 13412–13423.
Lundstrom K, Grayson RJ, Richard PJ and Francois J (1999). Efficient in vivo expression of a reporter gene in a rat brain after injection of recombinant replication-deficient Semliki Forest virus. Gene Therapy and Molecular Biology 3: 15–23.
MacDonald GH and Johnston RE (2000). Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. Journal of Virology 74: 914–922.
Madsen KG, Hansen CM, Madsen ES, Strandbygaard B, Botner A and Sorensen KJ (1998). Sequence analysis of porcine reproductive and respiratory syndrome virus of the American type collected from Danish swine herds. Archives in Virology 143: 1683–1700.
Meeusen ENT, Walker J, Peters A, Pastoret PP and Jungersen G (2007). Current status of veterinary vaccines. Clinical Microbiology Reviews 20: 489–510.
Minke JM, Audonnet JC and Fischer L (2004). Equine viral vaccines: the past, present and future. Veterinary Research 35: 425–443.
Mogler M (2009). Replicon particle PRRSV vaccine provides partial protection from challenge. Proceedings of the American Association of Swine Veterinarians 2009: 367–368.
Mogler M, Vander Veen R, McVicker J, Russell B and Harris DL (2010). Vaccination of pigs with PRRVENT or PRRSV-RP recombinant vaccines reduces viremia following heterologous challenge. Proceedings of the American Association of Swine Veterinarians 2010: 403–404.
Morris-Downes MM, Phenix KV, Smyth J, Sheahan BJ, Lilegvist S, Mooney DA, Liljestrom P, Todd D and Atkins GJ (2001). Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19: 1978–1988.
Neumann EJ, Kleibenstein J, Johnson C, Mabry JW, Bush EJ, Seitzinger AH, Green AL and Zimmerman JJ (2005). Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. Journal of the American Veterinary Medical Association 227: 385–392.
Nishimoto KP, Laust AK, Wang K, Kamrud KI, Hubby B, Smith JF and Nelson EL (2007). Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunology 20: 88–104.
Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH and Peters CJ (1996). Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14: 337–343.
Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, Hariharan MJ, Townsend K, Perri S, Mento SJ, Jolly DJ, Chang SMW, Schlesinger S and Dubensky TW Jr (1999). Stable alphavirus packaging cell lines for Sindbis virus- and Semliki Forest virus-derived vectors. Proceedings of the National Academy of Sciences of the United States of America 96: 4598–4603.
Pushko P, Geisbert J, Parker M, Jahrling P and Smith J (2001). Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Journal of Virology 75: 11677–11685.
Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE and Smith JF (1997). Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239: 389–401.
Rayner JO, Dryga SA and Kamrud KI (2002). Alphavirus vectors and vaccination. Reviews in Medical Virology 12: 279–296.
Reap EA, Dryga SA, Morris J, Rivers B, Norberg PK, Olmsted RA and Chulay JD (2007a). Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clinical and Vaccine Immunology 14: 748–755.
Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, Esch RE, Negri S, Burnett B, Graham A, Olmsted RA and Chulay JD (2007b). Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25: 7441–7449.
Saxena S, Dahiya SS, Sonwane AA, Patel CL, Saini M, Rai A and Gupta PK (2008). A Sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine 26: 6592–6601.
Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R and Perdue ML (2000). Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal Infection with Hong Kong-origin H5N1 viruses. Virology 278: 55–59.
Smerdou C and Liljestrom P (1999). Two-helper RNA system for production of recombinant Semliki Forest virus particles. Journal of Virology 73: 1092–1098.
Strauss J and Strauss E (1994). The alphaviruses: gene expression, replication, and evolution. Microbiological Reviews 58: 491–562.
Sun SQ, Liu T, Guo HC, Yin SH, Shang YJ, Feng X, Liu ZX and Xie QG (2007). Protective immune responses in guinea pigs and swine induced by a suicidal DNA vaccine of the capsid gene of swine vesicular disease virus. Journal of General Virology 88: 842–848.
Sylte MJ, Hubby B and Suarez DL (2007). Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 25: 3769–3772.
Takkinen K (1986). Complete nucleotide sequence of the nonstructural protein genes of Semliki Forest virus. Nucleic Acids Research 14: 5667–5682.
Thorner AR, Lemckert AAC, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJE and Barouch DH (2006). Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. Journal of Virology 80: 12009–12016.
Uttenthal A, Parida S, Rasmussen TB, Paton DJ, Haas B and Dundon WG (2010). Strategies for differentiating infection in vaccinated animals (DIVA) for foot-and-mouth disease, classical swine fever and avian influenza. Expert Reviews of Vaccines 9: 73–87.
Vander Veen RL, Kamrud KI, Mogler MA, Loynachan AT, McVicker J, Owens G, Berglund P, Timberlake S, Whitney L, Smith J and Harris DL (2009). Rapid development of an efficacious swine vaccine for novel H1N1. PLoS Currents Influenza 1: RRN1123.
Vander Veen RL, Loynachan AT, Mogler MA, Russell BJ, Harris DL and Kamrud KI (2012). Safety, immunogenicity, and efficacy of an alphavirus-based swine influenza virus hemagglutinin vaccine. Vaccine 11: 1944–1950.
Volkova E, Gorchakov R and Frolov I (2006). The efficient packaging of Venezuelan equine encephalitis virus-specific RNAs into viral particles is determined by nsp1–3 synthesis. Virology 344: 315–327.
Weiss BG and Schlesinger S (1991). Recombination between Sindbis virus RNAs. Journal of Virology 65: 4017–4025.
Yu X, Xiao S, Fang L, Jiang Y and Chen H (2006). Enhanced immunogenicity to foot-and-mouth disease virus in mice following vaccination with alphaviral replicon-based DNA vaccine expressing the capsid precursor polypeptide (P1). Virus Genes 33: 337–344.
Zhao HP, Li N, Sun Y, Wang Y and Qiu HJ (2009a). Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice. Veterinary Immunology and Immunopathology 15: 158–166.
Zhao HP, Sun JF, Li N, Sun Y, Xia ZH, Wang Y, Cheng D, Qi F, Jin ML and Qiu HJ (2009b). Assessment of the cell-mediated immunity induced by alphavirus replicon-vectored DNA vaccines against classical swine fever in a mouse model. Veterinary Immunology and Immunopathology 129: 57–65.